Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4] Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding patent infringement claims [2][4] - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [4] Legal and Licensing Details - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents [4] - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications, ending all patent-infringement litigation against Moderna related to its COVID-19 vaccines [2][4] Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3] - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development through the invention of LNP delivery technology [3] Ongoing Litigation - Genevant continues litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 mRNA vaccine sales [4]

Core Viewpoint - Moderna has agreed to pay $950 million to resolve all global litigation related to its products, with no future royalties owed, providing clarity for its infectious disease portfolio [1] Group 1: Settlement Details - The settlement agreement is with Arbutus Biopharma Corporation and Genevant Sciences GmbH, resolving all litigation worldwide, including cases in the U.S. District Court for the District of Delaware [1] - The settlement covers all litigation related to Spikevax® and mRESVIA®, ensuring certainty for Moderna's full infectious disease portfolio [1] Group 2: Financial Implications - A corresponding charge is expected in Q1 2026, with the District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals [1] - There is a potential for additional payment contingent on the outcome of the appeal, but no accrual has been recorded for this potential payment as the loss is not considered probable [1] - Year-end cash and cash equivalents for 2026 are now expected to be in the range of $4.5 - $5.0 billion [1]

Financial Outlook and Strategy - Moderna anticipates up to 10% revenue growth in 2026, driven by new products and geographic expansion[2,138] - The company aims to improve gross margin by 10 percentage points over the next three years through volume increases, productivity improvements, and waste reduction[2,88] - Moderna is targeting cash breakeven in 2028, supported by a strong balance sheet and a $1.5 billion credit facility[2,131,138] - Projected cash costs are expected to reduce to $3.5-3.9 billion in 2027[138] Vaccine Portfolio - Seasonal vaccines are expected to be the backbone of Moderna's revenue growth over the next three years[27] - The company plans to expand its seasonal vaccine franchise to up to six approved products by 2028[2] - Moderna expects to enter the global flu vaccine market in the 2027/28 season with mRNA-1010, with regulatory filings expected by January 2026[67] - The company has submitted mRNA-1083 (Flu + COVID combo) for approval to Health Canada and is under review with the EMA[69] Oncology and Rare Disease Therapeutics - Moderna is investing cash generated from vaccines into oncology and rare disease therapeutics[10,34] - Investments in late-stage oncology and rare disease programs are expected to drive additional growth in 2027-2028[37,74] - The company is executing registrational studies in rare diseases and investing in early-stage autoimmune therapeutics[128]